The Journal of Experimental Medicine
VeriKine-HS Human IFN-Beta
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published 5 August 2002. doi:10.1084/jem.20020090
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 88K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cohen, J. L.
Right arrow Articles by Salomon, B. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cohen, J. L.
Right arrow Articles by Salomon, B. L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© Rockefeller University Press, 0022-1007/2002/8/401/ $5.00
The Journal of Experimental Medicine, Volume 196, Number 3, August 5, 2002 401-406


Brief Definitive Report

CD4+CD25+ Immunoregulatory T Cells : New Therapeutics for Graft-Versus-Host Disease



José L. Cohen, Aurélie Trenado, Douglas Vasey, David Klatzmann and Benoît L. Salomon

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Scientifique UMR 7087, Hôpital Pitié-Salpêtrière, 756651 Paris, France

Address correspondence to Benoît L. Salomon, Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, CNRS UMR 7087, Hôpital Pitié-Salpêtrière, 83, bd de l'Hôpital, 756651 Paris, France. Phone: 33-1-42-17-74-61; Fax: 33-1-42-17-74-62; E-mail: benoit.salomon{at}chups.jussieu.fr

CD4+CD25+ immunoregulatory T cells play a pivotal role in preventing organ-specific autoimmune diseases and in tolerance induction to allogeneic organ transplants. We investigated whether these cells could also control graft-versus-host disease (GVHD), the main complication after allogeneic hematopoietic stem cell transplantation (HSCT). Here, we show that the few CD4+CD25+ T cells naturally present in the transplant regulate GVHD because their removal from the graft dramatically accelerates this disease. Furthermore, the addition of freshly isolated CD4+CD25+ T cells at time of grafting significantly delays or even prevents GVHD. Ex vivo–expanded CD4+CD25+ regulatory T cells obtained after stimulation by allogeneic recipient-type antigen-presenting cells can also modulate GVHD. Thus, CD4+CD25+ regulatory T cells represent a new therapeutic tool for controlling GVHD in allogeneic HSCT. More generally, these results outline the tremendous potential of regulatory T cells as therapeutics.

Key Words: regulatory T cells • hematopoietic stem cell transplantation • GVHD • tolerance • in vivo animal models


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS